welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy

 Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, released the following statement on the report from the Institute for Clinical and Economic Review (“ICER”) on treatments for Duchenne muscular dystrophy:

Sarepta is committed to appropriately pricing therapeutics so that they are cost effective and believes that, done properly, evaluations such as those conducted by ICER could serve a valuable purpose.

With that said, however, ICER’s approach is fatally flawed as it relates to rare and genetic disease for a number of reasons. As a result, we have chosen not to participate in reviews by ICER until it adapts its model to address the inherent limitations and biases that compromise its evaluations of therapies intended to treat patients with serious, rare diseases.

Sarepta Therapeutics Statement On ICER Draft Evidence Report For Treatments For Duchenne Muscular Dystrophy